Muco – Obstructive patients with over expression of MUC5AC mucin protein are susceptible to mortality and morbidity. Effective treatment reducing MUC5AC hyper-production in the airway of the lung is not available and there is an arising interest to develop an effective and potent agent in the treatment of mucin induced lung disease.
SpliSense is developing an Antisense Oligonucleotide (ASO) drug, SPL5AC, that can modulate and lower MUC5AC expression and production in a specific manner and thus potentially reduce its levels in mucus, decrease mucus viscosity and accumulation in the airways, improve mucus clearance and reduce infection and inflammation in patients with muco-obstructive diseases.